Protagonist Therapeutics PTGX Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's stock-based comp?
- Protagonist Therapeutics (PTGX) reported stock-based comp of $14.52M in Q1 2026.
- How has Protagonist Therapeutics's stock-based comp changed year-over-year?
- Protagonist Therapeutics's stock-based comp increased by 5.2% year-over-year, from $13.8M to $14.52M.
- What is the long-term trend for Protagonist Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's stock-based comp has grown at a 29.4% compound annual growth rate (CAGR), from $16.4M to $45.97M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.